Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index; 6 of the 44 sources its claims cite were checked for support.
Abstract
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Overview
CoChat Summary
## TL;DR
Lutathera® ([177Lu]Lu-DOTA-TATE) is presented as the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy (PRRT) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The paper summarizes its mechanism, indication, dosing, manufacturing, and the clinical trial results that supported approval.
## Key findings
- Lutathera® was approved by the EMA in 2017 and the FDA in 2018; the paper also notes Canadian approval in 2019.
- Its active ingredient is [177Lu]Lu-DOTA-TATE, which combines lutetium-177 with the somatostatin analogue DOTA-TATE to target SSTR-expressing tumor cells and cause DNA single- and double-strand breaks.
- The recommended treatment schedule is four infusions of 7.4 GBq every 8 weeks; intervals may be extended to 16 weeks if dose-modifying toxicity occurs.
- In the NETTER-1 phase III trial (229 patients), progression-free survival favored [177Lu]Lu-DOTA-TATE plus octreotide LAR over high-dose octreotide LAR: 65% vs 11% of patients were progression-free at 20 months (p < 0.0001), median PFS was not reached vs 8.5 months, and objective response rate was 18% vs 3% (p < 0.001).
## Methods
- Narrative review/overview of Lutathera® covering chemical properties, clinical indication, application, pharmacology/pharmacokinetics, manufacturing, and regulatory status.
- Draws on published clinical studies and product monographs, including the Erasmus phase I/II study (1,214 patients) and the NETTER-1 phase III trial (229 patients).
- Summarizes reported trial endpoints and pharmacokinetic/dosimetry data from the cited studies rather than presenting new original analyses.
## Limitations
- The paper does not report any new original experimental or clinical data; it synthesizes prior literature and regulatory documents.
- The text makes evident that some sections are only brief summaries and refer readers to product monographs or cited studies for details; this limits methodological depth and reproducibility of the review’s own synthesis.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
5 Valid · 0 Not valid · 33 Not checked · 1 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The positive results of the multicenter phase-III clinical trial [16], NETTER-1, comparing the treatment with [177Lu]Lu-DOTA-TATE to the treatment with high doses of octreotide LAR, paved the way for its approval by national and international medicines agencies in America and Europe.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 4. Conclusions
What the sources say
- Partly supportedcites [16] Strosberg, 2017, NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.3. Pharmacology and Pharmacokinetics In a study by Reubi et al. [29], the SSTR subtype affinity profile of a number of somatostatin analogues was investigated, showing, e.g., that DOTA-TATE exhibits high affinity for human SSTR2 (IC50 of 1.5 ± 0.4 nM) with much less binding affinity for all other human SSTRs. Complexing this peptide with yttrium resulted in a comparable binding affinity profile and complexing with gallium in an even higher affinity for SSTR2 (IC50 of 0.2 ± 0.04 nM). [177Lu]Lu-DOTA-TATE shows high binding affinity for SSTR2 as well, and therefore binds to malignant cells with an upregulation of SSTR2 [8]. Upon binding to the receptor, the radiolabeled peptide becomes internalized into the cell and the β particle emission of 177Lu induces DNA single- and double-strand breaks, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions [8]. Figure 2 gives a simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE. Due to the range of the β particles in comparison to the diameter of a cell, the emitted β particles traverse several cells (10–1000) [30]. This effect has been termed “cross-fire effect” and is responsible for the possible destruction of multiple cells in the vicinity of the tracer-accumulating cell [31]. Using β particle emitters, the cross-fire effect is critical for the improvement of tumor dose homogeneity and for ensuring a sufficient dose for each cell [32]. Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31]. Owing to the nanomolar concentration (10 µg/mL; 6.3 × 10−3 nM) of the peptide in the sterile injection solution [8], no clinically relevant pharmacodynamic effects are expected. The pharmacokinetic properties of Lutathera® are described in the product monographs [8,27]. [177Lu]Lu-DOTA-TATE is immediately and completely bioavailable through i. v. injection and clears rapidly from blood. The effective half-life in blood in a study with 31 patients was determined to be 0.31 ± 0.13 h [33]. The effective blood elimination half-life is 3.5 ± 1.4 h [26]. Studies using non-radioactive [175Lu]Lu-DOTA-TATE showed that protein binding to human plasma is ca. 50% and that transchelation of lutetium to serum proteins is not occurring. Four hours after administration, [177Lu]Lu-DOTA-TATE shows uptake in kidneys, tumoral lesions, liver, and spleen, and in some patients, additionally in the pituitary gland and thyroid. Kidney uptake can be decreased by co-administration of amino acids (see above), which reduces the re-absorption of the radiopharmaceutical through the proximal tubules [34]. This is mandatory because the compound is primarily eliminated through the renal system. Data from the Erasmus phase-I/-II and NETTER-1 phase-III trials indicate that ca. 60% of the radiopharmaceutical is eliminated in the urine within 24 h post injection (p. i.) and ca. 65% within 48 h p. i. Metabolism of [177Lu]Lu-DOTA-TATE is negligible, as shown by radio-HPLC analysis of urine samples collected 48 h p. i. Radiation dosimetry of [177Lu]Lu-DOTA-TATE has been evaluated in 20 patients in clinical studies [15,27]. The critical organ is the bone marrow. However, with the recommended cumulative dose of 29.6 GBq (4 × 7.4 GBq), neither correlation of hematological toxicity with total administered radioactivity nor with bone marrow absorbed dose has been observed. The kidney is not a critical organ when co-administration of appropriate amino acids is conducted. The median radiation dose to the kidneys can be reduced by 47% (34% to 59%) with co-administration of amino acids [26]. Table 1 summarizes estimated radiation absorbed doses for Lutathera® in the NETTER-1 trial for main organs [26,27].
What the sources say
- Supportedcites [31] Haberkorn, 2017, The Future of Radioligand Therapy: α, β, or Both?, J. Nucl. Med. source
The discussion of the radiation-induced bystander effect (p. 1) explicitly defines it as neighboring cells that were not directly exposed to ionizing radiation behaving as though they were exposed. The Figure 1 caption (p. 2) likewise describes effects on neighboring, unexposed cells. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“The clinical indication of Lutathera® is the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2 grade) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults [15,27].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.1. Clinical Indication
What the sources say
- Not matchedcites [15] (2019, April 23). Lutathera® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf.
We searched by its title and found no matching paper.
- Not matchedcites [27] (2019, April 23). Product Monograph for LUTATHERATM for Canada. Available online: https://pdf.hres.ca/dpd_pm/00049099.pdf.
We searched by its title and found no matching paper.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“It could also be demonstrated that treatment with [177Lu]Lu-DOTA-TATE was safe and well tolerated [8].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 1. Introduction
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors.”
- Also stated in: § 4. Conclusions · plain
“Combining the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, [177Lu]Lu-DOTA-TATE delivers ionizing radiation specifically and selectively to tumor cells expressing SSTRs.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > Abstract
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Conclusions · plain
12 more claims
Create a free account to see all 39 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 3
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532 · cited 1×
“The development of these radiolabeled somatostatin ligands was a very long scientific journey that started with the first description of somatostatin more than 45 years ago [10].”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodAntibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight
Coenen, H. H., Gee, A. D., Adam, M., Antoni, G., Cutler, C. S., Fujibayashi, Y., Jeong, J. M., Mach, R. H., Mindt, T. L., Pike, V. W., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.09.004 · Cited by 226 · cited 1×
“In January 2018 (26 January 2018), Lutathera® ([177Lu]Lu-DOTA-TATE (for rules on nomenclature, see [1,2])) was approved by the FDA [3] for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.”
BackgroundElschot, M., Vermolen, B. J., Lam, M. G. E. H., de Keizer, B., van den Bosch, M. A. A. J., & de Jong, H. W. A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055742 · Cited by 209
Targeted α-therapy–past, present, future?
Brechbiel, M. W. (2007) · Dalton Transactions · doi:10.1039/b704726f · Cited by 151
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Research works printed but not linked: 3
- Erion, 1999, High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model [abstract], J. Nucl. Med., 40, 223
- Nagy, 2004, Radionuclide Therapy, Handbook of Nuclear Chemistry, Volume 4, 315
- Rolleman, 1996, Inhibition of Renal Uptake of Indium-111-DTPAOctreotide, J. Nucl. Med., 37, 1388
Cited by
Items 401–426 of 426
Is there a role for early SSTR-targeting PRRT in GEP-NET?
Ricciardello, G., Celesti, G., Bauckneht, M., Burger, I. A., Iagaru, A. H., Arco, M., Curatolo, S., Pagano, B., Amato, E., Auditore, L., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07974-4 · Cited by 1
“…longer progression-free survival (PFS), significantly higher response rate, and improved quality of life (QoL) among patients with well-differentiated, unresectable or metastatic, progressive SSTRs-pos-itive GEP-NETs [ 5 ], leading to its approval by EMA and FDA as a second-line therapy [ 6–8 ].”
Esnault, M., Gaschet, J., Touchefeu, Y., Ansquer, C., & Lugat, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102118
CD70-targeted platform for diagnosing and treating multiple myeloma
Li, J., Yan, H., Wang, X. G., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014058
Novel Substituted Carboxamides as SSTR4 Agonists
Rong, J., & Liang, S. H. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00294
Fedrigo, R., Harsini, S., Murtha, L., Vasconcelos, J. P. S., Uribe, C., Wilson, D. C., Bénard, F., Alberts, I., Martineau, P., & Loree, J. M. (2026) · Neuroendocrinology · doi:10.1159/000552968
Sanwick, A. M., Haugh, K. N., Osborne, D., et al. (2026) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2026.109655
Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe
Kao, W.-S. M., Grimaldi, C., Samuels, Z. V., et al. (2026) · JACS Au · doi:10.1021/jacsau.6c00555
Maskur, M., Sugiharto, Y., Sarmini, E., Sekaringtyas, F. C., Sulaiman, Billah, A. A., Pujianti, L. A., Triyatna, F., Ritawidya, R., & Ridwan, M. F. (2026) · Urania Jurnal Ilmiah Daur Bahan Bakar Nuklir · doi:10.55981/urania.2026.13640
Fang, C.-B., Xu, Z., Zhu, S., et al. (2026) · 化学学报 · doi:10.6023/a26010030
Furuya, Y., Tsujimoto, M., Asai, T., et al. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02256-3
Ytterbrink, C., Pettersson, D., Shubbar, E., Helou, K., Johansson, M., & Forssell-Aronsson, E. B. (2026) · Scientific Reports · doi:10.1038/s41598-026-61293-0
Olmez, S. (2026) · JSM Clinical Oncology and Research · doi:10.47739/oncology.1081
Grasso, S., Varallo, A., Gaudieri, V., Klain, M., Pastore, R., Arena, S., Oliviero, C., Buono, M., Manzi, D., Schiano, R., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070889
Targeted radionuclide-drug conjugates: Current status and perspectives
Yichao, Y., Liu, X., Jiang, Y., & Sun, L. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119190
Passalacqua, E., Barberi, G., Amico, P., Martino, S. D., & Rosa, M. D. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00420b
Parghane, R. V., & Basu, S. K. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006139
Le, K., McKenna, T. R., Mallari, P. M., Ahmed, S.-B. Z., Ziemba, A. M., Buck, M. E., & Moore, S. J. (2026) · Protein Engineering Design and Selection · doi:10.1093/protein/gzag022
Emerging strategies for efficient separation of medical β-radionuclides
Qiu, L., Lyu, J., Liao, J., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.180667
Theranostics: integrating diagnostics and therapy for precision medicine and personalized healthcare
Khanna, K., Kumar, P., Rajagopal, M. S., Maki, M. A. A., Jubair, N. K., Kamal, W. H. B. W., & Janib, S. M. (2026) · Health and Technology · doi:10.1007/s12553-026-01093-8
“…capacity for fabrication and surface manipulation of nanoparticles (NPs) with targeting compounds, such as antibodies, peptides, or proteins [35, 46] in combination with therapeutic and/or radioactive agents, it can be classified as a nanotheranostic delivery approach, which is an innovative…”
Tong, X., He, Y., Liu, H., Guo, W., Huang, W.-G., Li, P., Wang, L., Zhu, Y., Cai, L., (22749799), H.-Q. Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00687
Decoding the uptake pathway of nanoparticles in tumor cells: mechanisms, developments and challenges
Chen, Z., Zhou, L., Li, S., & Zhang, X. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.104054 · Cited by 1
Chang, M., Chen, C.-T., Lee, W.-C., Tai, Y., & Chiang, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101198
Medina-Guevara, Y., Rojas, H. C., Idrissou, M. B., Lepesevich, L. L., Wehner, L. E., Lindsey, M. J., Pinchuk, A. N., Carston, A. M., Clemons, N. C., Montoya, A. F. M., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00252
Kiranmayi, G. V. N., Harikrishnan, N., Ming, L. C., & Srikanth, K. (2026) · Wiley eBooks · doi:10.1002/9781394402557.ch5
Radiohalogenated Tetrazines for Click Chemistry-Mediated Pretargeted Radioimmunotherapy
Cornejo, M., Dehlavi, G., Samuels, Z. V., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00618
Theranostics in the Central Nervous System
Chen, M., Pyatigorskaya, N., Benayoun, M. D., Ponisio, M. R., Kosović, V., & Franceschi, A. M. (2026) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2026.07.015
Metadata
- Authors
- Hennrich, U., & Kopka, K.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Hennrich, Ute
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-07-29
- Volume
- 12
- Issue
- 3
- Pages
- 114
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789871
- OpenAlex
- W2965362447
- Semantic Scholar
- 541d92ea7d4ff1ddec5cefec2755259d1aa26d0e
- Cited by
- 440
- References
- 26
- Citations by year
- 2026: 58 · 2025: 87 · 2024: 88 · 2023: 61 · 2022: 58 · 2021: 46 · 2020: 38 · 2019: 3
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-DOTATATE, lutetium-177, peptide receptor radionuclide therapy, somatostatin receptors, DOTATATE, gastroenteropancreatic neuroendocrine tumors, radiopharmaceuticals, targeted radionuclide therapy, DNA double-strand breaks, cancer cell death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].](https://figures.cochat.ai/paper-figures/b252f6f0df3d4eceb221f630640ad0bc/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-1.jpg)
![Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.](https://figures.cochat.ai/paper-figures/56d8de000b344458a3f6939340017c5b/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-2.jpg)